Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-mercaptopyridine)(PiPr3)2 moieties, its synthesis, and its use as a catalyst.

Abstract: Synthesis of four coordinated palladium complexes and their applications in light emitting devices thereof.

Abstract: The current invention relates to novel platinum(II) based organometallic materials. These materials show high emission quantum efficiencies and low self-quenching constant. Also provided are high efficiency, green to orange emitting organic light-emitting diode (OLED) that are fabricated using platinum(II) based organometallic materials as the light-emitting material. The organometallic materials of the invention are soluble in common solvents; therefore, solution process methods such as spin coating and printing can be used for device fabrication. The devices fabricated from these materials show low efficiency roll-off.

Abstract: The present invention relates to asymmetric catalysts, including redox-reconfigurable asymmetric catalysts. Methods of producing compounds having one or more stereocenters using the asymmetric catalysts of the present invention are also disclosed.

Abstract: The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.

Abstract: Provided is a compound including an activated metal and a ligand, a carbon dioxide (CO2) absorbent including the compound, a method of preparing the CO2 absorbent, and a method of removing CO2.

Abstract: A copper(I) complex is represented by the following Formula (1): [Cua(XS)b(L)c], wherein, L is triphenylphosphine, acetonitrile, tri-iso-butylphosphine, or a substituted or unsubstituted heterocyclic compound having 5 to 18 carbon atoms, a is an integer from 2 to 6, b is an integer from 2 to 6, c is an integer from 0 to 6, X is a substituted or unsubstituted aryl group, substituted or unsubstituted carbazole, or PR3, where R is a substituted or unsubstituted phenyl group or a substituted or unsubstituted cyclohexyl group.

Abstract: The present invention describes metal salen complexes having dianionic counterions. Such complexes can be readily precipitated and provide an economical method for the purification and isolation of the complexes, and are useful to prepare novel polymer compositions.

Abstract: Described are novel platinum (II) containing organometallic materials. These materials show green to orange emissions with high emission quantum efficiencies. Using the materials as emitting materials; pure green emitting organic light-emitting diodes can be fabricated. Since the novel platinum (II) containing organometallic materials are soluble in common solvents, solution process methods such as spin coating and printing can be used for device fabrication.

Abstract: A novel transition metal trimer compound/catalyst is disclosed. A method of increasing the overall mass transfer rate of acid gas scrubbing solvents utilizing that catalyst is also provided.

Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use in the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.

Abstract: Photosensitive compounds for use in a method of treating a disease or condition are described. The photosensitive compounds have the formula R—Y, wherein R is a ruthenium complex and Y is at least one sulphur-containing photoreleasable group, and the compounds comprise at least one ruthenium-sulphur bond; or a pharmaceutically acceptable salt, solvate, ester or amide, such that upon influence of visible or near infra-red light (400-1400 nm) in vivo, said at least one ruthenium-sulphur bond is broken, thereby generating a pharmacologically active compound.

Abstract: The invention relates to C—H activated olefin metathesis catalyst compounds, the preparation of such compounds, and the use of such catalysts in the metathesis of olefins and olefin compounds, more particularly, the use of such catalysts in Z selective olefin metathesis reactions. In general, the catalyst compounds of the invention comprise a Group 8 metal (M), an alkylidene moiety (?CR1R2), or more generally (?(C)mCR1R2), an anionic ligand (X1), two or three neutral ligands (L1, L2, and L3) and a 2-electron anionic donor bridging moiety (Q*) that forms a chelate ring structure in conjunction with L1 and M.

Abstract: The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials, dental bonding agents or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such dental restorative materials may help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: The present invention provides a cathode catalyst for an air secondary cell having both excellent oxygen reduction activity and excellent water oxidation activity, and an air secondary cell that uses the catalyst. The present invention relates to a cathode catalyst for an air secondary cell in which the catalyst contains a polynuclear metal complex.

Abstract: The present invention relates to a novel nickel complex and its derivatives, which mimic the active site of Ni-containing superoxide dismutase (NiSOD). The five-coordinate Ni(II) and Ni(III) complexes or their derivatives, and six-coordinate derivatives have the following structures of formula (I) and (II): The nickel complexes and their derivatives of the invention act as anti-oxidants or free radical scavengers. The invented nickel complexes can be used in the preparation of medicines, health foods or cosmetics for human, animals and plants, or can be used in environmental or soil protection.

Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.

Abstract: The present invention relates to a novel nickel complex and its derivatives, which mimic the active site of Ni-containing superoxide dismutase (NiSOD). The five-coordinate Ni(II) and Ni(III) complexes or their derivatives, and six-coordinate derivatives have the following structures of formula (I) and (II): The nickel complexes and their derivatives of the invention act as anti-oxidants or free radical scavengers. The invented nickel complexes can be used in the preparation of medicines, health foods or cosmetics for human, animals and plants, or can be used in environmental or soil protection.

Abstract: The invention relates to a process for preparing primary amines by alcohol amination of alcohols with ammonia with the elimination of water, where the alcohol amination is carried out under homogeneous catalysis in the presence of at least one complex catalyst which comprises ruthenium and at least one at least bidental donor ligand, but no anionic ligands.

Abstract: Novel grafted dinuclear metal complexes having formula (I) or of formula (II) wherein M represents a metal ion, and also the use thereof as sensors in a method for detecting and/or characterising cellular microparticles.

Abstract: Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.

Abstract: The present invention relates to a novel nickel complex and its derivatives, which mimic the active site of Ni-containing superoxide dismutase (NiSOD). The five-coordinate Ni(II) and Ni(III) complexes or their derivatives, and six-coordinate derivatives have the following structures of formula (I) and (II): The nickel complexes and their derivatives of the invention act as anti-oxidants or free radical scavengers. The invented nickel complexes can be used in the preparation of medicines, health foods or cosmetics for human, animals and plants, or can be used in environmental or soil protection.

Abstract: An iridium complex is disclosed, which has a structure represented by the following formula (I): wherein each of Z1 and Z3 represents an atomic group for forming a nitrogen-containing heteroaryl group or a nitrogen-containing heterocycloalkenyl group; Z2 represents an atomic group for forming an aryl group, a heteroaryl group, a cycloalkenyl group or a heterocycloalkenyl group; Y represents an atomic group for forming a 5-membered nitrogen-containing heterocycloalkenyl group; each of R1, R2, R3 and R4 represents a hydrogen atom or a substituent; m is 1 or 2; a, b and d is 0 or any positive integer; and c is an integer of from 0 to 2.

Abstract: The present invention relates to novel micro or mesoporous metal organic frameworks (MOFs) which contain as ligands piperidine based phosphonic acids, as well as a method of synthesising such MOFs and uses of the MOFs themselves.

Abstract: A metal complex dye, containing a ligand LL1 having a structure represented by Formula (I): wherein R1 and R2 represent a specific substituent; L1 and L2 represent a group composed of at least one kind of group selected from the group consisting of an ethenylene group, an ethynylene group and an arylene group, and conjugate with R1 or R2, and the bipyridine; the ethenylene group and the arylene group may be substituted or unsubstituted; R3 and R4 represent a substituent; n1 and n2 represent an integer of 0 to 3; A1 and A2 represent an acidic group or a salt thereof; and n3 and n4 represent an integer of 0 to 3.

Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.

Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.

Abstract: Phosphorescent materials and devices with improved device manufacturing, fabrication, stability, efficiency, and/or color.

Abstract: The present invention provides compounds of Formula I: along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.

Abstract: Provided is a compound including residues derived from a compound represented by Formula (1) and a divalent aromatic group, wherein the number of the residues is 2 to 4, the number of the divalent aromatic group is 1 to 3, and the sum of the numbers of the residues and the divalent aromatic group is 3 to 5. In Formula (1), each of Y1 to Y4 represent a group represented by any of the following Formula (2); in the following Formula (2), R? represents a hydrogen atom or a hydrocarbyl group; each of P1 to P4 represents an atomic group forming a heterocyclic ring containing Y1 to Y4; P5 and P6 represent an atomic group forming an aromatic ring or a heterocyclic ring; Q1 and Q2 represent a linking group or a direct bond; and Z1 and Z2 represent a hydrogen atom or a group represented by any of the following Formula (3); and in the following Formula (3), R? represents a hydrogen atom or a hydrocarbyl group.

Abstract: The present invention provides bimetallic complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to one or more active metal centers of the complex.

Abstract: Metal complex of Zinc(II) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of 172.4. This paper describes the synthesis, characterization and biological results of the said metal complex containing deprotonated 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligand.

Abstract: The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to the active metal center of the complex.

Abstract: The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to the active metal center of the complex.

Abstract: The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to the active metal center of the complex.

Abstract: Metal complex of Copper (II) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the copper complex has been analyzeThis paper describes the synthesis and characterization of the said metal complex containing deprotonated 3-[1-(2-pyridyl) ethylidene]hydrazinecarbodithioate ligand (FIG. 1).

Abstract: Metal complex of Manganese(II) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of 132.2 This paper describes the synthesis, characterization and biological results of the said metal complex containing deprotonated 3-[1-(2-pyridyl)ethylidene]hydrazinecarbodithioate ligand (FIG. 1).

Abstract: The present invention provides compounds of Formula I: (I) along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.

Abstract: The present invention relates to the use of group 3 post-metallocene complexes based on sterically encumbered bis(naphthoxy)pyridine and bis(naphthoxy)thiophene ligands in the ring-opening polymerisation of polar monomers such as, for examples, lactones, lactides, cyclic carbonates.

Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Abstract: Metal complex of Cobalt (11) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of (0.5). This paper describes the synthesis, characterization and biological results of the said metal complex containing the deprotonated 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligand (FIG. 1).

Abstract: Metal complex of Iron (U) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-ER spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of (0.5). This paper describes the synthesis, characterization and biological results of the said metal complex containing deprotonated 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligand (FIG. 1).

Abstract: A metal complex dye, containing a ligand LL1 having a structure represented by Formula (I): wherein R1 and R2 represent a specific substituent; L1 and L2 represent a group composed of at least one kind of group selected from the group consisting of an ethenylene group, an ethynylene group and an arylene group, and conjugate with R1 or R2, and the bipyridine; the ethenylene group and the arylene group may be substituted or unsubstituted; R3 and R4 represent a substituent; n1 and n2 represent an integer of 0 to 3; A1 and A2 represent an acidic group or a salt thereof; and n3 and n4 represent an integer of 0 to 3.

Abstract: Personal care compositions including dried zinc pyrithione are provided.

Abstract: The present invention provides a light-emitting organic platinum complex, a light-emitting material containing this complex, and a functional device containing this complex. The light-emitting organic platinum complex is represented by any one of the following structural formulae: where: Z represents either —(CH2)n— or —CH2(CH2OCH2)mCH2—, where n represents 7 to 14, and m represents 3 to 4; A represents either an optionally condensed aromatic hydrocarbon ring or an optionally condensed heteroaromatic ring; R is a substituent group for A and represents H (unless n of Z in the structural formula (1) is 7 to 13), a halogen, a C1-C6 alkyl group, a C1-C6 alkenyl group, a C1-C6 alkynyl group, a C1-C6 alkoxy group or the like.

Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials, dental bonding agents or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such dental restorative materials may help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: Metal bleach catalysts that are complexes of a transition-metal and a dioxo ligand, cleaning compositions comprising such metal bleach catalysts, and methods of using such metal bleach catalysts, are described herein.